Phase 2 Mesothelioma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with certain types of advanced or spreading cancer that cannot be surgically removed, confirmed by lab testing — including ovarian, endometrial, lung, breast, cervical, or mesothelioma cancers (the specific type accepted depends on which part of the trial you may qualify for — confirm with trial site)
- You have already received previous cancer treatments that are known to help with your type of cancer
- Your cancer can be measured on scans at the start of the trial
- For some parts of the trial, you have a specific type of ovarian cancer (such as high grade serous, fallopian tube, or primary peritoneal cancer) and your cancer has stopped responding to platinum-based chemotherapy (platinum-resistant)
- For some parts of the trial, you have received between 1 and 4 previous treatment courses, depending on which part of the trial applies to you (confirm with trial site)
- For some parts of the trial involving ovarian cancer, you have previously received a medication called bevacizumab (or a similar approved drug)
- For some parts of the trial, if you have a BRCA gene mutation and responded to platinum chemotherapy, you must have also received a type of treatment called a PARP inhibitor
- For some parts of the trial, you have endometrial cancer (any type except sarcoma or neuroendocrine tumors)
- For some parts of the trial involving endometrial cancer, you have previously received platinum-based chemotherapy and an immunotherapy drug called a PD-(L)1 inhibitor
Who may not be able to join:
- You have had a history of lung inflammation (not caused by infection) that required steroid treatment within the last 2 years, currently have this condition, or scans cannot rule out this condition at the start of the trial
- You have previously been treated with a specific type of drug called a topoisomerase 1 inhibitor-based antibody drug conjugate (confirm with trial site if unsure whether your past treatment falls into this category)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Official, Genmab
Phone: +4570202728
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Parts A, B, and D - Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]; Parts A, and D - Dose Limiting Toxicity (DLT); Parts C, E, F, G, H, I, and J- Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR, Parts C and F) or Investigator (Part E, G, I, and J) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Part K (US Participants Only) - Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Findings by Holter
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.